Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.
Expanded indication for AKEEGA ® (niraparib and abiraterone acetate dual-action tablet) plus prednisone marks the first FDA-approved precision medicine combination treatment for patients with ...
Leading scientists are advocating for annual prostate cancer screening for men with BRCA1 and BRCA2 gene mutations. Experts at the London-based Institute of Cancer Research (ICR) state that the ...
Treatment with Akeega plus prednisone and androgen deprivation therapy (ADT) significantly reduced the risk of radiographic progression or death by 54% compared to placebo/abiraterone acetate plus ...
Decision making is evidence based and must be shielded from lobbying The NHS draft recommendation against routine prostate ...
The UK National Screening Committee has opened a 12-week public consultation on whether and how prostate cancer screening ...
It’s a problem with not nearly enough attention. Prostate cancer hits men hard all over the world—it’s one of the biggest ...
The FDA approved niraparib and abiraterone acetate (Akeega) in combination with prednisone for treating BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC), the agency announced on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback